FDA publishes current list of Drug Master Files (Type II)

Recommendation
Tuesday, 23 September 2025 13.00 - 17.00 h
All holders of a Drug Master File (DMF) for the US market are required to pay a DMF fee when first authorizing the reference of their DMF in a generic application. In addition, Type II API DMFs must undergo an FDA initial completeness assessment. This assessment is described in the FDA Draft Guideline "Initial Completeness Assessments for Type II API DMFs under GDUFA" which was published in October 2012.
If the DMF passes the initial Completeness Assessment, the DMF number will be made publicly available on FDA’s website. The list of Drug Master Files is now available for download.
Related GMP News
03.09.2025USP: Chapters 'Balances <41>' and 'Weighing on an Analytical Balance <1251>' final
27.08.2025ECHA: 'PFAS' Restrictions updated
20.08.2025EMA/HMA: Nitrosamine Report published
13.08.2025IPEC: Risk Assessment Guide for Excipients now available
30.07.2025EMA: Chapter 4 - new Requirements for GMP Documentation?